94 related articles for article (PubMed ID: 7928472)
1. A dosimetric model for intrathecal treatment with 131I and 67Ga.
van Dieren EB; van Lingen A; Roos JC; Huijgens PC; Barendsen GW; Teule GJ
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):447-54. PubMed ID: 7928472
[TBL] [Abstract][Full Text] [Related]
2. Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution.
van Dieren EB; Plaizier MA; van Lingen A; Roos JC; Barendsen GW; Teule GJ
Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):197-204. PubMed ID: 8823276
[TBL] [Abstract][Full Text] [Related]
3. Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model.
Shinohara A; Hanaoka H; Sakashita T; Sato T; Yamaguchi A; Ishioka NS; Tsushima Y
Ann Nucl Med; 2018 Feb; 32(2):114-122. PubMed ID: 29238922
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides.
Kairemo KJ; Tenhunen M; Jekunen AP
Cancer Gene Ther; 1998; 5(6):408-12. PubMed ID: 9917096
[TBL] [Abstract][Full Text] [Related]
5. Radiotoxic effect and dosimetry of 67GA in multicellular spheroids as compared to single cells of the lymphoma cell line U715.
van Leeuwen-Stok AE; Schuurhuis GJ; Dräger Am; Visser-Platier AW; van Dieren EB; Teule GJ; Huijgens PC
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):507-17. PubMed ID: 8655374
[TBL] [Abstract][Full Text] [Related]
6. [99mTc reduces clonogenic survival after intracellular uptake in NIS-positive cells in vitro more than 131I].
Wendisch M; Freudenberg R; Drechsel J; Runge R; Wunderlich G; Kotzerke J
Nuklearmedizin; 2010; 49(4):154-60. PubMed ID: 20490428
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
[TBL] [Abstract][Full Text] [Related]
8. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
[TBL] [Abstract][Full Text] [Related]
9. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
10. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.
Muthuswamy MS; Roberson PL; Ten Haken RK; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):165-72. PubMed ID: 8641915
[TBL] [Abstract][Full Text] [Related]
11. 5-(125I)-iododeoxyuridine and the Auger effect: biological consequences and implications for therapy.
Bloomer WD; Adelstein SJ
Pathobiol Annu; 1978; 8():407-21. PubMed ID: 364377
[TBL] [Abstract][Full Text] [Related]
12. Can occult metastases be treated by radioimmunotherapy?
Dunn RM; Juweid M; Sharkey RM; Behr TM; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2656-9. PubMed ID: 9406721
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis.
Richardson RB; Kemshead JT; Davies AG; Staddon GE; Jackson PC; Coakham HB; Lashford LS
Eur J Nucl Med; 1990; 17(1-2):42-8. PubMed ID: 2083542
[TBL] [Abstract][Full Text] [Related]
14. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
Bao A; Zhao X; Phillips WT; Woolley FR; Otto RA; Goins B; Hevezi JM
Med Phys; 2005 Jan; 32(1):200-8. PubMed ID: 15719971
[TBL] [Abstract][Full Text] [Related]
15. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution.
Fujimori K; Fisher DR; Weinstein JN
Cancer Res; 1991 Sep; 51(18):4821-7. PubMed ID: 1893374
[TBL] [Abstract][Full Text] [Related]
16. Decreased uptake after fractionated ablative doses of iodine-131.
Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
[TBL] [Abstract][Full Text] [Related]
17. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters.
Roeske JC; Chen GT; Atcher RW; Pelizzari CA; Rotmensch J; Haraf D; Montag A; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1539-48. PubMed ID: 2262379
[TBL] [Abstract][Full Text] [Related]
18. Radiobiological modeling of combined targeted 131I therapy and total body irradiation for treatment of disseminated tumors of differing radiosensitivity.
Amin AE; Wheldon TE; O'Donoghue JA; Barrett A
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):323-30. PubMed ID: 8407407
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.
Kemshead JT; Hopkins K; Pizer B; Papanastassiou V; Coakham H; Bullimore J; Chandler C
Br J Cancer; 1998 Jun; 77(12):2324-30. PubMed ID: 9649153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
